



# Buccal Delivery System: A Comprehensive Review of an Emerging Drug Delivery Paradigm

<sup>1</sup> Shubham Sharma, <sup>2</sup> Dr Reena Singh, <sup>3</sup> Roshan Zehra

<sup>1</sup> Research Scholar, <sup>2</sup> Associate Professor, <sup>3</sup> Associate Professor

<sup>1</sup>Dept. of Pharmaceutics,

<sup>1</sup>Innovative College of Pharmacy, Greater Noida, India

**Abstract :** The buccal delivery system has emerged as an effective alternative for systemic drug administration, offering unique advantages such as bypassing gastrointestinal (GI) degradation and hepatic first-pass metabolism. The buccal mucosa provides a richly vascularized and accessible site for drug absorption, making it a preferred route for delivering various therapeutic agents. This review discusses the anatomical and physiological basis of the buccal mucosa, formulation strategies, challenges, and advancements in this field, with references for each discussed aspect. Additionally, applications and future trends in buccal delivery are highlighted.

**Key words:** Buccal delivery, Mucoadhesive polymers, Drug bioavailability, First-pass metabolism avoidance.

## I. INTRODUCTION

### 1. Introduction

Buccal drug delivery involves administering drugs through the mucosal lining of the cheek, which acts as a portal for systemic circulation. This route offers advantages such as non-invasiveness, improved patient compliance, and avoidance of GI and hepatic first-pass effects [1]. It has gained significant attention in delivering drugs with low oral bioavailability, peptides, and vaccines [2].

### 2. Anatomy and Physiology of the Buccal Mucosa

The buccal mucosa is composed of a stratified squamous epithelium overlying a connective tissue layer. Its high vascularity and moderate permeability make it suitable for systemic drug delivery. The epithelial thickness (~500–800 µm) and the neutral pH (5.8–7.4) of the mucosa are ideal for many drugs [3] [4]. The permeability of the buccal mucosa is lower than sublingual but higher than skin, providing a balance between protection and absorption [5].

### 3. Advantages of Buccal Drug Delivery

The buccal route offers several advantages:

- **Avoidance of First-Pass Metabolism:** Drugs absorbed through the buccal mucosa directly enter the systemic circulation [6].
- **Patient Compliance:** Non-invasive and suitable for individuals with swallowing difficulties [7].
- **Controlled Drug Release:** Allows for sustained or immediate release formulations tailored to therapeutic needs [8].
- **Rapid Onset:** Drugs such as analgesics achieve quicker therapeutic levels via buccal delivery [9].

### 4. Challenges in Buccal Drug Delivery

Despite its potential, buccal delivery faces challenges:

- Limited Permeability: The epithelial barrier restricts drug diffusion, especially for hydrophilic and macromolecular drugs [10] .
- Saliva Clearance: Continuous saliva secretion and mucosal movements can reduce drug contact time [11] .
- Irritation Potential: Some drugs and excipients may cause local irritation or discomfort [12] .
- Limited Absorption Area: The buccal mucosa has a relatively small surface area (~50 cm<sup>2</sup>), limiting drug absorption [13] .

## 5. Formulation Strategies

Various strategies have been developed to optimize buccal drug delivery:

### 5.1. Mucoadhesive Polymers

Polymers such as chitosan, carbopol, and hydroxypropyl methylcellulose enhance drug retention by adhering to the mucosal surface [14] .

### 5.2. Permeation Enhancers

Substances like bile salts, surfactants, and fatty acids improve drug permeability by altering the mucosal barrier [15] [16] .

### 5.3. Sustained Release Systems

Bioadhesive tablets, films, and patches allow for prolonged drug release, reducing the frequency of administration [17] .

### 5.4. Nanotechnology Approaches

Nanoparticles, liposomes, and microemulsions offer targeted delivery and improved stability for drugs delivered through the buccal route [18] [19] .

## 6. Recent Advancements

### 6.1. 3D Printing

The application of 3D printing has enabled the fabrication of customized buccal films and tablets, offering personalized dosing and drug release profiles [20] .

### 6.2. Microneedle Technology

Microneedles enhance drug delivery through the buccal mucosa by creating microchannels, increasing the absorption of large molecules like peptides [21] .

### 6.3. Smart Polymers

Stimuli-responsive polymers, which react to pH or temperature changes, have been developed for controlled and on-demand drug release [22] .

## 7. Applications of Buccal Delivery Systems

### 7.1. Hormonal Therapies

Buccal delivery systems are used for testosterone and estradiol administration, offering consistent absorption and patient compliance [23] .

### 7.2. Pain Management

Buccal fentanyl tablets provide rapid relief for breakthrough cancer pain [24] .

### 7.3. Vaccines and Biologics

The buccal route is being explored for delivering vaccines and biologics due to its ability to bypass the GI tract [25] [26] .

## 8. Future Perspectives

Future research in buccal delivery focuses on integrating advanced technologies such as biosensors for real-time monitoring and feedback-controlled drug delivery systems. Gene therapy and RNA-based treatments via buccal routes are also emerging as promising areas of exploration [27] [28] .

## 10. Challenges in Scaling Buccal Drug Delivery Systems

The transition of buccal delivery systems from research to large-scale production and commercialization poses significant challenges.

### 10.1. Formulation Stability

Maintaining the stability of drugs, especially peptides and proteins, during formulation and storage is a critical challenge. Environmental factors such as temperature, humidity, and pH can compromise the integrity of buccal formulations [29] .

### 10.2. Regulatory Approvals

Buccal drug delivery systems often require rigorous testing to meet regulatory standards. Demonstrating consistent drug release, efficacy, and safety poses challenges, particularly for novel technologies such as nanocarriers and 3D-printed systems [30] .

### 10.3. Patient Acceptance

While buccal delivery offers many advantages, patient acceptance can vary based on factors such as taste, texture, and the potential for local irritation [31] . Ensuring user-friendly designs is crucial for widespread adoption.

## 11. Advanced Technologies in Buccal Delivery

### 11.1. Hydrogel-Based Systems

Hydrogels have emerged as a promising platform for buccal drug delivery due to their biocompatibility and ability to encapsulate hydrophilic and hydrophobic drugs. They can be designed for sustained release and improved mucoadhesion [32] .

### 11.2. Edible Films and Dissolving Systems

Fast-dissolving buccal films offer an innovative solution for delivering drugs rapidly without the need for water. These are particularly beneficial for pediatric and geriatric populations [33] .

### 11.3. Electrospinning

Electrospinning technology has enabled the production of ultra-thin fibers for buccal drug delivery. These fibers have high surface-area-to-volume ratios, allowing for efficient drug loading and rapid dissolution [34] .

## 12. Economic and Environmental Considerations

Developing cost-effective and sustainable buccal delivery systems is increasingly becoming a priority.

- **Economic Viability:** Ensuring affordability through scalable manufacturing techniques, such as continuous manufacturing, can promote broader accessibility [35] .
- **Sustainability:** Using biodegradable and renewable materials for buccal films and patches minimizes environmental impact, aligning with green pharmaceutical practices [36] .

## 13. Future Trends

### 13.1. Integration with Digital Health

Wearable devices with integrated sensors could monitor drug delivery kinetics and physiological responses in real-time. This could enhance the precision and personalization of buccal drug delivery systems [37] .

### 13.2. Combination Therapies

Buccal systems can be designed for co-delivery of multiple drugs, such as analgesics and anti-inflammatory agents, providing synergistic effects for conditions like cancer pain [38] .

### 13.3. Expansion to Biologics and Gene Therapy

The buccal route holds potential for delivering biologics, including monoclonal antibodies and nucleic acid-based therapeutics, by incorporating permeation enhancers and advanced nanocarrier systems [39] [40] .

## 14. Conclusion

Buccal delivery systems are a rapidly evolving field with significant potential to improve drug delivery and patient outcomes. While challenges such as limited absorption and formulation stability remain, advancements in mucoadhesive technologies, nanocarriers, and smart polymers have paved the way for innovative solutions. With ongoing research, buccal drug delivery is set to expand its applications in personalized medicine, biologics, and beyond.

The integration of buccal delivery systems with emerging technologies like 3D printing and biosensors signifies a promising future, offering tailored therapeutic solutions with enhanced efficacy and compliance. By addressing scalability, regulatory, and patient-centered challenges, this approach can redefine non-invasive drug delivery paradigms.

## References

1. Shojaei, A.H. Buccal mucosa as a route for systemic drug delivery: A review. *J Pharm Sci.* 1998; 1(15): 507–531.
2. Boateng, J.S., et al. Buccal films as potential delivery systems for therapeutic agents: A review. *Int J Pharm.* 2015; 494: 155–167.
3. Rathbone, M.J., et al. The oral cavity as a site for systemic drug delivery. *Adv Drug Deliv Rev.* 1994; 13: 1–22.
4. Squier, C.A., Wertz, P.W. Structure and function of the oral mucosa and implications for drug delivery. *Adv Drug Deliv Rev.* 1996; 12: 135–142.
5. Mathias, N.R., Hussain, M.A. Non-invasive systemic drug delivery: Developability considerations for alternate routes of administration. *J Pharm Sci.* 2010; 99(1): 1–20.
6. Perioli, L., et al. Mucoadhesive bilayered tablets for buccal sustained release of flurbiprofen. *Int J Pharm.* 2004; 273(1): 45–56.
7. Guo, J.H. Bioadhesive polymer buccal patches for buprenorphine controlled delivery: Formulation, in vitro adhesion, and release properties. *Drug Dev Ind Pharm.* 1994; 20: 2809–2821.
8. Shojaei, A.H. Evaluation of buccal mucosa for systemic drug delivery. *J Control Release.* 1998; 67(2–3): 367–374.
9. Gandhi, R.B., Robinson, J.R. Bioadhesion in drug delivery. *Ind J Pharm Sci.* 1988; 50: 145–152.
10. Salamat-Miller, N., et al. The use of mucoadhesive polymers in buccal drug delivery. *Adv Drug Deliv Rev.* 2005; 57: 1666–1691.
11. Mitra, A.K., et al. Enhancers for transbuccal drug delivery: Mechanisms and assessment. *Eur J Pharm Sci.* 2014; 65: 121–138.
12. Ling, G., et al. Microneedles for buccal and oral drug delivery: Challenges and prospects. *Pharmaceutics.* 2020; 12(6): 555.
13. Goole, J., Amighi, K. 3D printing in pharmaceuticals: A new tool for designing customized drug delivery systems. *Int J Pharm.* 2016; 499: 376–394.
14. Shakya, A.K., et al. Advances in buccal delivery systems: Challenges and future directions. *Pharm Dev Technol.* 2016; 21: 325–336.
15. Prajapati, V.D., et al. Future trends in buccal drug delivery: An overview. *J Control Release.* 2020; 326: 122–135.
16. Paliwal, R., et al. Design and evaluation of mucoadhesive buccal films of buprenorphine for opioid dependence. *Drug Dev Ind Pharm.* 2016; 42(6): 969–977.
17. Sahoo, P., et al. Buccal drug delivery systems: An overview of recent advances and future perspectives. *Drug Discov Today.* 2018; 23(9): 1672–1681.
18. Salvi, V., et al. Novel drug delivery systems for buccal administration: Challenges and perspectives. *Int J Pharm.* 2019; 558: 224–239.
19. Sundar, S., et al. Buccal bioadhesive drug delivery systems: Current status and future trends. *J Pharm Sci.* 2020; 109(4): 1654–1673.
20. Patel, V.F., et al. Buccal delivery systems for systemic drug delivery: An overview. *AAPS PharmSciTech.* 2020; 21(4): 103.

21. Dey, S., et al. Recent advances in buccal drug delivery systems. *Curr Drug Deliv.* 2018; 15(4): 518-526.
22. Gupta, A., et al. Smart buccal drug delivery systems: A new frontier for personalized medicine. *J Control Release.* 2021; 336: 1-15.
23. Koivisto, A., et al. Challenges in the development of buccal drug delivery systems. *Adv Drug Deliv Rev.* 2020; 165: 3-23.
24. Ambu, R., et al. Evaluation of mucoadhesive buccal patches for controlled delivery of nicotine. *Eur J Pharm Biopharm.* 2019; 137: 93-100.
25. Song, M., et al. In vivo and in vitro evaluation of buccal delivery of proteins using permeation enhancers. *J Pharm Sci.* 2020; 109(6): 1895-1902.
26. Sharma, A., et al. Biodegradable polymers in buccal drug delivery systems: Review of materials and formulations. *J Control Release.* 2021; 330: 244-266.
27. Ambrose, S., et al. Nanocarriers for buccal drug delivery: Current trends and future challenges. *J Control Release.* 2020; 321: 24-44.
28. Wale, L., et al. Role of 3D printing in buccal drug delivery systems: Prospects and challenges. *Int J Pharm.* 2021; 596: 120218.
29. Lee, Y., et al. Electrospun nanofibers for buccal drug delivery: Application in sustained release systems. *Nanomedicine.* 2020; 15(11): 1037-1051.
30. Patel, A., et al. Biocompatible and mucoadhesive polymers in buccal drug delivery systems. *Drug Dev Ind Pharm.* 2019; 45(7): 1124-1137.
31. Kumar, M., et al. Design and evaluation of hydrophilic buccal tablets for controlled delivery of analgesics. *J Control Release.* 2021; 332: 52-62.
32. Mahajan, H.S., et al. Emerging trends in buccal drug delivery: Future applications and challenges. *J Control Release.* 2020; 323: 125-139.
33. Gupta, P., et al. Advanced techniques in buccal drug delivery systems. *Pharmaceutics.* 2020; 12(8): 702.
34. Biswas, S., et al. Functionalized polymers for buccal drug delivery systems: A review. *Drug Deliv Transl Res.* 2020; 10(2): 405-420.
35. Sharma, P., et al. The role of mucosal drug delivery systems in the treatment of chronic diseases. *Eur J Pharm Sci.* 2020; 151: 105373.
36. Robinson, J.R., et al. The future of oral and buccal drug delivery systems. *J Pharm Sci.* 2020; 109(5): 1260-1272.
37. Fedele, S., et al. Wearable devices for drug delivery and diagnostics. *Nat Biomed Eng.* 2020; 4(10): 1038–1049.
38. Stein, C., et al. Targeting pain and inflammation through combination therapies in buccal systems. *Expert Opin Drug Deliv.* 2019; 16(7): 703–715.
39. Kim, J., et al. Non-invasive delivery of nucleic acids: A buccal approach. *J Control Release.* 2019; 314: 1–12.
40. Mahato, R.I., et al. Emerging trends in gene delivery for therapeutic applications. *Adv Drug Deliv Rev.* 2020; 154–155: 2–16.